A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Context Therapeutics
• Treatments: Anastrozole; Onapristone; Progesterone

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis at MSK of either (1) granulosa cell ovarian cancer, (2) low grade serous ovarian/ primary peritoneal cancer, or (3) endometrioid endometrial cancer; with PR expression ≥1% by IHC on archival tissue taken within the prior 3 years or new biopsy if no archival tissue is available. IHC results do not have to be from MSK.

• Measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension. Each lesion must be ≥10mm when measured by CT or MRI. Lymph nodes must be ≥15mm in short axis when measured by CT or MRI

• Patients must have had one prior chemotherapy regimen for management of disease. Note:

additional lines of chemotherapy, biologic or immunotherapy are allowed.

• Recovery from effects of recent surgery, radiotherapy, or chemotherapy

• At least 4 weeks out from their last dose of radiation therapy

• At least 4 weeks post-op from any major surgical procedure

• At least 3 weeks out from their last dose of chemotherapy and/or biologic/targeted therapy

• Must be ≥ 18 years of age

• Karnofsky Performance Status (KPS) of ≥ 70%

• Women of child-bearing potential must have a negative pregnancy test within 14 days prior to commencement of study treatment

• Women of child bearing potential must use an effective form of contraception during study and for at least 6 months after completion of study treatment

• Laboratory Test Findings performed within 14 days prior to initiation of study drug showing:

• Bone marrow function:

• Absolute neutrophil count (ANC) ≥ 1,000/mcL

• Platelets ≥ 75,000/mcL

• Hemoglobin ≥ 8 g/dL

• Renal function:

°Creatinine ≤ 1.5 x ULN

• Hepatic function:

• Bilirubin ≤ 1.5 x ULN

• AST and ALT ≤ 2.5 x ULN

• Resolution of all acute toxic effects of prior therapy to NCI CTCAE (Version 5.0) Grade ≤ 1, with the exception of unresolved Grade 2 neuropathy and Grade 2 alopecia, which are allowed

• Patient has recovered from any prior radiotherapy

• Patients must be able to swallow tablets whole, without crushing

Exclusion Criteria:

• History of another invasive malignancy (other than non-melanoma skin cancer or curatively treated in situ carcinoma) with evidence of disease within the past 3 years

• History of prior hormonal therapy (i.e., megesterol acetate, tamoxifen or aromatase inhibitors) for treatment of cancer within 28 days before starting study drug

• Any psychological, familial, sociological or geographic condition that would potentially hamper compliance with the study protocol

• Known brain metastasis which have not been treated or showed stability for ≥ 6 months

• Patient has received an oral or IV corticosteroid within the prior 28 days and requires chronic corticosteroid therapy (excludes use of steroid premeds for CT allergy)

• Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95mmHg) despite medical treatment. Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.

• Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic event within the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline

• Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition, drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study drug absorption

• Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study

• Use of any prescription medication during the prior 28 days of first onapristone dosing that the investigator judges is likely to interfere with onapristone activity; specifically strong inhibitors or inducers, or sensitive substrates of cytochrome P450 CYP3A4. Investigators should consult the following table of clinically-relevant products http://medicine.iupui.edu/CLINPHARM/ddis/clinical-table.